Drugs /

spironolactone

Back to Drugs List

Overview

Trade Name(s):
Aldactone
NCI Definition [1]:
A synthetic 17-spironolactone corticosteroid with potassium-sparing diuretic, antihypertensive, and antiandrogen activities.Spironolactone competitively inhibits adrenocortical hormone aldosterone activity in the distal renal tubules, myocardium, and vasculature. This agent may inhibit the pathophysiologic effects of aldosterone produced in excess by various types of malignant and benign tumors.

Clinical Trials

View Clinical Trials for spironolactone

Spironolactone has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating spironolactone, 2 are phase 1/phase 2 (2 open).

BCR-ABL1 Fusion, CBFB-MYH11 Fusion, and CD33 Expression are the most frequent biomarker inclusion criteria for spironolactone clinical trials.

Acute myeloid leukemia and secondary acute myeloid leukemia are the most common diseases being investigated in spironolactone clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Spironolactone
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating spironolactone and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Aldactone, sc 9420, spl, 17-hydroxy-7alpha-mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma lactone, acetate
NCIT ID [1]:
C840
SNOMED ID [1]:
F-61C72

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.